Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
Earnings Data
Report Date
Nov 05, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
5.96Last Year’s EPS
6.61Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments, such as leadership changes, revenue growth in some areas, and upcoming FDA decisions, alongside challenges in the oncology segment and revenue guidance adjustments.Company Guidance
Leadership Transition
Renee Gala was appointed as the new CEO, effective August 11, 2025, succeeding Bruce Cozadd. This transition is expected to build on Jazz Pharmaceuticals' momentum and drive long-term growth.
FDA PDUFA Action Dates
Jazz Pharmaceuticals is anticipating key FDA PDUFA action dates for dordaviprone on August 18, 2025, and for Zepzelca on October 7, 2025, which could potentially expand treatment options for patients.
Revenue Growth
The second quarter of 2025 saw total revenue surpass $1 billion, with Xywav showing a 13% year-over-year increase and Epidiolex maintaining strong underlying demand.
Oncology Pipeline Developments
Positive progress in the oncology pipeline includes the potential approval of dordaviprone for H3 K27M-mutant diffuse glioma and Zepzelca in first-line maintenance for extensive-stage small cell lung cancer.
Ziihera Approval
Ziihera received conditional marketing authorization from the European Commission for second-line HER2-positive biliary tract cancer, enhancing Jazz's oncology portfolio.
JAZZ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
JAZZ Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 05, 2025 | $113.20 | $105.93 | -6.42% |
May 06, 2025 | $111.17 | $101.44 | -8.75% |
Feb 25, 2025 | $139.67 | $144.17 | +3.22% |
Nov 06, 2024 | $111.55 | $119.08 | +6.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Jazz Pharmaceuticals (JAZZ) report earnings?
Jazz Pharmaceuticals (JAZZ) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).
What is Jazz Pharmaceuticals (JAZZ) earnings time?
Jazz Pharmaceuticals (JAZZ) earnings time is at Nov 05, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is JAZZ EPS forecast?
JAZZ EPS forecast for the fiscal quarter 2025 (Q3) is 5.96.